David A. Siegel Keros Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 17,100 shares of KROS stock, worth $266,418. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,100

Previous 119,500 85.69%

Holding current value

$266,418

Previous $1.22 Million 81.27%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$9.55 - $15.11 $977,920 - $1.55 Million	-102,400 Reduced 85.69%	17,100 $228,000
Q1 2025 May 15, 2025	BUY	$10.15 - $16.1 $1 Million - $1.59 Million	98,800 Added 477.29%	119,500 $1.22 Million
Q4 2024 Feb 14, 2025	BUY	$15.64 - $70.0 $215,832 - $966,000	13,800 Added 200.0%	20,700 $327,000
Q3 2024 Nov 14, 2024	SELL	$41.68 - $58.07 $454,312 - $632,963	-10,900 Reduced 61.24%	6,900 $400,000
Q2 2024 Aug 14, 2024	BUY	$44.58 - $66.89 $156,030 - $234,115	3,500 Added 24.48%	17,800 $813,000
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $590,018 - $1.01 Million	14,300 New	14,300 $946,000
Q4 2021 Feb 14, 2022	SELL	$36.95 - $62.89 $694,660 - $1.18 Million	-18,800 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$29.27 - $43.71 $330,751 - $493,923	11,300 Added 150.67%	18,800 $744,000
Q2 2021 Aug 16, 2021	BUY	$42.4 - $70.11 $127,200 - $210,330	3,000 Added 66.67%	7,500 $319,000
Q1 2021 May 17, 2021	BUY	$54.0 - $75.28 $243,000 - $338,760	4,500 New	4,500 $277,000

Others Institutions Holding KROS

# of Institutions

156

Shares Held

38.6M

Call Options Held

834K

Put Options Held

969K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $401M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account